This characteristic is particularly relevant in the context of renal cell carcinoma, bladder, and ovarian cancer, where the high expression of PD-1 on CD103+ TRM cells is thought to be a key factor in the efficacy of anti-PD-1 therapies (51–53). The gene discussed is ITGAE; the disease is renal cell carcinoma.